Latest Report Asthma Therapeutics Market to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations

By -

Meager as the growth may look, it is important to note that the asthma therapeutics market is on the verge of witnessing widespread generic erosion. Patent expirations are expected to eat into the revenues of blockbuster drugs such as Advair (fluticasone propionate/salmeterol xinafoate), Xolair (omalizumab), and Symbicort (budesonide/formoterol fumarate). This sea change in the global asthma therapeutics market will be brought about by the entry of new players as well as the growing pervasiveness of asthma itself.


The report notes that there is unparalleled industry interest in monoclonal antibodies and biologics, with the former enjoying more attention within the indication. Clinical trials have shown encouraging results for new monoclonal antibodies; some of these include: Lebrikizumab, mepolizumab, dupilumab target Interleukins (IL), and reslizumab. 

These molecules are seen to be beneficial in inadequately controlled or severe eosinophilic asthma. 

These drugs, which will constitute a sizeable chunk of the personalized asthma therapeutics market, will target a small section of asthma patients, but will carry steep price tags and still drive market growth. This, market experts predict, will ostensibly offset the detrimental effects of generic erosion.

Healthcare systems worldwide are already heaving the burden of growing incidences of asthma, show figures from the World Health Organization.

 The disease—which affected an estimated 300 million people worldwide in 2007—is projected to spread to 400 million people by 2025. While the better part of asthma patients are able to bring their symptoms under control using products currently available on the market, there is still a considerable chunk of asthma victims that cannot do so. 

This unmet need in the global asthma therapeutics market has kindled the interest of pharmaceutical companies and other industry players.

This has proven highly beneficial to the current asthma pipeline, with several promising molecules reported to be on the anvil. A number of these molecules are in the later stages of development and are expected to hit the asthma therapeutics market as early as 2015-16.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures

 2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Etiology
2.4 Pathophysiology
2.5 Symptoms
2.6 Diagnosis
2.7 Assessment of Disease Severity
2.8 Treatment
2.9 Treatment Algorithm
2.10 Treatment Segments
2.10.1 ICS Monotherapy for the Maintenance Treatment of Asthma
2.10.2 Singulair (montelukast sodium) as First-Line Maintenance Therapy
2.10.3 ICS/LABA Combination Therapy
2.10.4 Add-on Therapies

 3 Marketed Products
3.1 Overview
3.2 ICS for the Maintenance Treatment of Asthma
3.2.1 Arnuity (fluticasone furoate) – GSK
3.3 ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma
3.3.1 Advair (fluticasone propionate and salmeterol xinafoate) – GSK
3.3.2 Symbicort (budesonide and formoterol fumarate) – AstraZeneca, Co-Promotion with Astellas Pharma
3.3.3 Dulera (mometasone furoate and formoterol fumarate) – Merck
3.3.4 Relvar/Breo (vilanterol trifenatate and fluticasone furoate) – GlaxoSmithKline/Theravance
3.4 Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma
3.4.1 Xolair (omalizumab) – Novartis and Genentech
3.4.2 Singulair (montelukast) – Merck
3.4.3 Spiriva (tiotropium bromide) – Boehringer Ingelheim
3.5 Heat Maps for Marketed Products

 4 Asthma Pipeline
4.1 Overview
4.2 Pipeline Analysis by Stage of Development, Molecule Type and Program Type
4.3 Pipeline Analysis by Molecular Target
4.4 Asthma Clinical Trial Landscape
4.4.1 Clinical Trial Failure Rates
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.4.4 Comparative Clinical Trial Metrics Analysis
4.5 Promising Pipeline Molecules
4.5.1 Mepolizumab – GSK
4.5.2 Reslizumab – Teva Pharmaceutical
4.5.3 Lebrikizumab – Roche/Genentech
4.5.4 Dupilumab – Regeneron Pharmaceuticals in Collaboration with Sanofi
4.5.5 Masitinib – AB Science
4.6 Heat Map and Competitor Matrix for Pipeline Products

 5 Market Forecast to 2020
5.1 Geographical Markets
5.2 Global Market
5.3 North America
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Top Five Countries of Europe
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Usage Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Drivers and Barriers for the Asthma Market
5.6.1 Drivers
5.6.2 Barriers

 6 Strategic Consolidations
6.1 Co-development Deals
6.1.1 Sepracor Enters into Co-Development Agreement with Nycomed for Ciclesonide
6.1.2 NeoStem Enters into Agreement with University of California to Develop Human Regulatory T Cells
6.1.3 Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies
6.2 Licensing Deals
6.2.1 Amgen Enters into Licensing Agreement with Kyowa Hakko Kirin – Terminated
6.2.2 Mundipharma Enters into Licensing Agreement with SkyePharma
6.2.3 MAP Pharmaceuticals Enters into Licensing Agreement with AstraZeneca – Terminated
6.2.4 Orexo Enters into Licensing Agreement with Janssen Pharmaceuticals – Terminated
6.2.5 Aslan Pharma Enters into Licensing Agreement with CSL for CSL-334

 7 Appendix
7.1 All Pipeline Drugs by Phase of Development
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 Phase I
7.1.4 Phase II
7.1.5 Phase III
7.1.6 Pre-registration
7.2 Market Forecasts to 2020
7.2.1 Global
7.2.2 US
7.2.3 Canada
7.2.4 UK
7.2.5 France
7.2.6 Germany
7.2.7 Italy
7.2.8 Spain
7.2.9 Japan
7.3 References
7.4 Abbreviations
7.5 Research Methodology
7.5.1 Secondary Research
7.5.2 Marketed Product Profiles
7.5.3 Late-Stage Pipeline Candidates
7.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
7.5.5 Product Competitiveness Framework
7.5.6 Pipeline Analysis
7.5.7 Forecasting Model

About Us:

Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. Headquartered in New York, U.S., MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact
State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States
Telephone: +1-518-618-1030
Website: http://www.mrrse.com/

Comments

Post a Comment

Popular posts from this blog

New reports Acetone Market Global Industry Analysis and Opportunity Assessment, 2014 – 2020

By -
Image
Research Reports Search Engine (MRRSE) announces the addition of a new report titled ‘ Acetone Market: Global Industry Analysis and Opportunity Assessment, 2014–2020’ to its database. The report finds that global acetone consumption stood at 5.9 million tonnes in 2014, and is poised to grow at a meager 3% CAGR from 2014 to 2020 to reach a little over 7.21 million tonnes by 2020. The report has been published by Future Market Insights (FMI). Global Acetone Market Analysis Forecast: The key drivers identified by the study are: The chemical sector’s dependence on acetone as a solvent, the use of acetone as a chemical in several processes, and the escalating use of BPA in the global automobile sector. On the other hand, the report warns that hurdles such as increasingly stringent government mandates for the chemical industry and the growing acceptance of bio-based acetone will restrict growth to some degree. In order to offer highly detailed insights into various face
Read more

Global Industrial Logistics Robots Market Shares, Status, Opportunities, Market Forecasts, 2014 to 2020

By -
The main benefits of incorporating industrial logistics robots are doing tasks that people cannot or will not perform, minimizing cost of labor, reducing the frequency as well as severity of injuries to workers, enabling processes that are speedier, more efficient, and organized, minimizing product damage, avoiding duplication, and mitigating loss arising from theft. To Get Browse Full Report with TOC: http://www.mrrse.com/reports/industrial-logistics-robots-market Developing industrial logistics robots is a rather tedious process that requires high capital and this often results in the postponement of investment. Achieving this feat is the biggest challenge at the moment. Logistics robots need to be customized according to the needs of a specific industry and this renders the process even more expensive. Another challenge that arises from the technological shift is the task of training new and existing staff to be able to handle and use these new systems. Logistic rob
Read more

Global Insulation (Fiberglass, Plastic Foam, Mineral Wool and Others) Market Residential Construction, Industrial Trends and Forecast 2014 – 2020

By -
The global insulation market will expand at an 8.0% CAGR during the forecast period. The global insulation market was valued at US$37.87 billion in 2013 and is estimated to reach a total value of US$64.91 billion in 2020. To Get Browse Full Report with TOC: http://www.mrrse.com/reports/insulation-market Product-wise, the global market for insulation is broadly segmented into fiberglass, plastic foam, mineral wool, and others. Fiberglass held the lion’s share of the demand in the worldwide insulation market with 42% in 2013. Alternatively, other insulation materials such as plastic foam experienced a decline in demand in the past few years due the fluctuating prices of raw materials, particularly crude oil. Geographically, distinctive trends can be seen in the developed and developing regions.   To Get Download Full Report with TOC: http://www.mrrse.com/enquiry/insulation-market According to the latest predictions, the global population will exceed 7.5 billio
Read more